Observational studyFuture oncology (London, England)2024

Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.

Valentina Guarneri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.